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Abstract
Background:  The 'Perception of Anti-Coagulant Treatment Questionnaire' (PACT-Q) was
developed to assess patients' expectations of, and satisfaction with their anticoagulant treatment.
This questionnaire needs to be finalised and psychometrically validated.
Methods: The PACT-Q was included in the United States, the Netherlands and France into three
phase III multinational clinical trials conducted to evaluate efficacy and safety of a new long-acting
anticoagulant drug (idraparinux) compared to vitamin K antagonist (VKA). PACT-Q was
administered to patients with deep venous thrombosis (DVT), atrial fibrillation (AF) or pulmonary
embolism (PE) at Day 1, to assess patients' expectations, and at 3 and 6 months to assess patients'
satisfaction and treatment convenience and burden. The final structure of the PACT-Q (Principal
Component Analysis – PCA – with Varimax Rotation) was first determined and its psychometric
properties were then measured with validity of the structure (Multitrait analysis), internal
consistency reliability (Cronbach's alpha coefficients) and known-group validity.
Results:  PCA and multitrait analyses showed the multidimensionality of the "Treatment
Expectations" dimension, comprising 7 items that had to be scored independently. The
"Convenience" and "Burden of Disease and Treatment" dimensions of the hypothesised original
structure of the questionnaire were combined, thus resulting in 13 items grouped into the single
dimension "Convenience". The "Anticoagulant Treatment Satisfaction" dimension remained
unchanged and included 7 items. All items of the "Convenience" and "Anticoagulant Treatment
Satisfaction" dimensions displayed good convergent and discriminant validity. The internal
consistency reliability was good, with a Cronbach's alpha of 0.84 for the "Convenience" dimension,
and 0.76 for the "Anticoagulant Treatment Satisfaction" dimension. Known-group validity was
good, especially with regard to occurrence of thromboembolic events within 3 months from
randomisation.
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Conclusion: The PACT-Q is a valid and reliable instrument that allows the assessment of patients'
expectations and satisfaction regarding anticoagulant treatment, as well as their opinion about
treatment convenience of use. Its two-part structure – assessment of expectations at baseline in
the first part, and of convenience, burden and treatment satisfaction in the second – was validated
and displays good and stable psychometric properties. These results are not sufficient to
recommend the use of satisfaction as primary endpoint in clinical trials; further validation work is
needed to support the interpretation of PACT-Q dimension scores. However, this first validation
makes the PACT-Q an appropriate measure for use in clinical and pharmacoepidemiological
research, as well as in real-life studies.
Trial Registration: (ClinicalTrials.gov numbers, NCT00067093, NCT00062803 and
NCT00070655).
Background
Oral vitamin K antagonists (VKA) are effective and com-
monly used anticoagulant agents for the secondary pre-
vention of venous thromboembolic disease and the
prevention of systemic embolism in patients with atrial
fibrillation [1]. However, because of patients' monitoring
requirements, their inherent limitations in daily life (e.g.
diet and activities) and the considerable inter-individual
variability in pharmacodynamic effect, the burden of VKA
on patients' daily life is highly significant, especially when
given as long-term therapy [2-4]. Together with possible
side effects such as bleedings, anticoagulant treatment
may negatively affect patients' health-related quality of
life (HRQoL) and treatment satisfaction, which in turn is
likely to result in the decrease of the treatment effective-
ness and ultimately in its failure [5-9]. Patients' satisfac-
tion with treatment mainly depends on their previous
experiences of similar treatment to which they compare
their new treatment, as well as on their expectations [10].
Thus, especially when clinical outcomes regarding treat-
ment efficacy and tolerance are rare and undistinguisha-
ble between different treatments, information about
patients' satisfaction with their treatment and HRQoL is
highly valuable. Surprisingly, despite the large use of VKA,
no specific questionnaire was available to assess patients'
satisfaction with their treatment and to evaluate their
unmet needs. Therefore, the Perception of Anti-Coagulant
Treatment Questionnaire (PACT-Q) was developed [11]
as a means to investigate the burden of disease in patients
with deep venous thrombosis (DVT), pulmonary embo-
lism (PE) or atrial fibrillation (AF), with specific focus on
patients' satisfaction with anticoagulant treatment and
treatment convenience. The questionnaire was adminis-
tered in the United States, the Netherlands and France
during international phase III clinical trials in patients
with DVT, PE or AF. These studies aimed at evaluating the
efficacy and safety of the new anticoagulant drug -idra-
parinux- injected subcutaneously once a week, compared
to VKA. The trials were multicentre, international, ran-
domised in two arms (VKA versus idraparinux), open-
label and assessor-blind.
In order to be fully acceptable as a meaningful endpoint
in clinical trials, the structure of a questionnaire has to be
validated, its scoring rules established and its psychomet-
ric properties demonstrated. In this paper, we present the
finalisation, i.e. scoring and validation of the original
structure of the questionnaire. The psychometric valida-
tion of the resulting dimensions is also presented.
Methods
The original PACT-Q
The original PACT-Q consists of two parts and contains 27
items [11]: the PACT-Q1, composed of a single dimension
(7 items), covering the expectations of patients regarding
their anticoagulant treatment, is to be administered
before treatment initiation; the PACT-Q2, composed of 3
dimensions covering the convenience of use of the treat-
ment (11 items), burden of disease and treatment (2
items) and satisfaction with the anticoagulant treatment
(7 items) as perceived by the patient, is to be administered
to patients once the treatment is ongoing [11]. All the
items of PACT-Q1 and PACT-Q2 parts are to be answered
on a 5-point Likert scale. The questionnaire was simulta-
neously developed in French, American English and
Dutch following a rigorous development process, in
which the data collected from the patients were given par-
ticular importance [11]. It was further translated and
adapted into 11 different country-specific versions follow-
ing recommended linguistic validation procedures that
included forward and backward translations by native
speakers [12].
PACT-Q administration
The PACT-Q was administered during phase III clinical
trials (DVT Clinical Study Protocol 64717/EFC3491; PE
Clinical Study Protocol 64714/EFC 3484; AF Clinical
Study Protocol 64720) as secondary endpoint in multi-
centre studies conducted in Europe (Austria, Belgium,
Czech Republic, Denmark, France, Germany, Italy, the
Netherlands and Poland), North America (Canada and
the United States) and Oceania (Australia and New Zea-
land), with patients with DVT, AF or PE. All three trialsHealth and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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were randomised, open-label and assessor-blind, and
were conducted in accordance with the principles stated
in the Declaration of Helsinki. Patients who provided an
oral consent prior to their inclusion participated in the
study. At Day 1, patients were asked to complete the
PACT-Q1 part of the questionnaire; at 3 month (M3) and
6 month (M6), patients were asked to complete the PACT-
Q2 part.
Definition of the study populations
Patients included in the analyses had at least one PACT-
Q1 and one PACT-Q2 completed and assessable (i.e. 50%
of items completed) at Day 1 and M3, respectively, and
did not violate the protocol for PACT-Q administration
along the whole study (Figure 1). As the PACT-Q was orig-
inally developed in French, American English and Dutch,
only patients from France, the United States and the Neth-
erlands were included in the study populations. In order
to control learning bias and for the purpose of the valida-
tion [13], two populations were pre-specified: the "scor-
ing and initial validation" population subset was
constituted of 452 patients with either DVT, AF or PE and
from either the United States, the Netherlands or France;
the "robustness" population subset was constituted of
200 AF patients from either the United States or the Neth-
erlands. The "pooled" population (n = 652), correspond-
ing to the "scoring and initial validation" population
subset combined with the "robustness" population sub-
Flowchart of the population included and participating in the study Figure 1
Flowchart of the population included and participating in the study.
 
TOTAL 
(patients with at least one PACT-Q received) 
3427 
PACT-Q2 received at M3  PACT-Q1 received  PACT-Q2 received at M6 
2950 3319 2327
PACT-Q1 assessable*  PACT-Q2 assessable* at M3  PACT-Q2 assessable* at M6 
3319 2950 2327
PACT-Q1 assessable and PACT-Q2 assessable at M3 
2620
No major protocol violation 
1919
Pre-specified “scoring and initial 
validation” population 
Pre-specified “robustness” 
population 
200  452 
 “Pooled” population   “Responsiveness” population
652 404
 
*At least 50% of the items are completed 
**Patients from the United States, the Netherlands and France only; remaining patients were used for treatment 
effect analyses (manuscript in preparation) 
** Health and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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set, was used to determine the PACT-Q psychometric
properties. Patients who answered at least 50% of the
PACT-Q2 items at M6 were included in the responsiveness
analysis of PACT-Q2 ("responsiveness" population sub-
set).
Statistical analyses
One should note that although the clinical trial was open-
label, statistical analyses were blind to treatment attribu-
tion, i.e. no distinction was made between the treatment
arms that patients were randomly allocated to.
Finalisation: scoring and initial validation of PACT-Q original structure
Principal Component Analysis (PCA) with Varimax Rota-
tion is often used to assess the hypothetical structure of an
instrument, by observing how the different items are
spontaneously grouped into factors [14]. In our case, PCA
was performed to check whether the factorial structure of
PACT-Q reproduces the number and the type of dimen-
sions that were hypothesised during the development
step. Multitrait analysis (MA) defining the item conver-
gent validity criterion (correlation between each item and
its own dimension is considered satisfactory if it achieves
 0.40) and the item discriminant validity criterion (each
item should have a higher correlation with its own dimen-
sion than with the other dimensions) was performed to
ascertain the consistency of the dimensions [15].
The internal consistency reliability of the dimensions
[16], i.e. the extent to which individual items are consist-
ent with each other and reflect a single underlying con-
struct, was assessed by the determination of Cronbach's
alpha coefficient [17]. A value of 0.70 or above is recom-
mended for group comparisons [18]. A Multiple Factorial
Analysis (MFA) was carried out to analyse the relationship
between PACT-Q1 and PACT-Q2 [19]. MFA assesses sev-
eral sets of variables defined on the same set of individu-
als, and allows computation of a summary statistic
referred to as the RV coefficient (vector correlation coeffi-
cient) [20]. RV value ranges from 0 to 1; the closer to 1 the
RV, the more similar the configuration of the two sets of
variables.
Validation and assessment of the psychometric properties of the 
PACT-Q dimensions
Validity is the degree to which the instrument measures
what it is supposed to measure [21-23]. Several types of
validity were assessed. The validation of the conceptual
model was assessed by performing MA with description of
item convergent and discriminant validity [15]. Scale-
scale correlation was evaluated in order to test the con-
struct validity of the questionnaire. Floor and ceiling
effects were measured to check that there was no issue
related to a high percentage of patients having the lowest
or the highest possible score on any one scale. Clinical
validity evaluates the extent to which the questionnaire is
able to detect variability amongst patients with different
clinical severity levels. Known-group validity can be eval-
uated when differences in scores are expected between
groups of patients that differ on relevant variables. Clini-
cal and known-group properties were assessed amongst
groups of patients defined according to age, gender, inter-
national normalized ratio (INR – patients at risk of embo-
lism, INR < 2; patients with less risk of embolism, INR >
3), prior medication, thromboembolic events within the
3 months following randomisation, and time they spent
in the 2–3 INR range between randomisation and M3.
Internal consistency reliability of the dimensions of the
PACT-Q was again evaluated, by determination of the
Cronbach's alpha coefficient [17]. Responsiveness refers
to the ability of a questionnaire to detect important
changes over a period of time [24]; it was assessed for the
"Convenience" and "Anticoagulant Treatment Satisfac-
tion" dimensions of the PACT-Q2 over M3 and M6, by
determining the Effect-Size (ES) and Standardised
Response Mean (SRM) [25-27]. A Wilcoxon signed rank
test was performed in order to compare the change to 0. A
Kruskal-Wallis test was performed to test the hypothesis
that the change in scores was significantly different across
the different groups of patients. The PACT-Q responsive-
ness was tested for groups of patients defined according to
the primary efficacy outcome (i.e. thromboembolic event
within 3 months from randomisation consisting in stroke
or a non-central nervous system systemic embolism for AF
patients, and a PE or DVT event for PE and DVT patients
respectively) and the time spent in the 2–3 INR range
between randomisation and M6 visits. The threshold for
statistical significance was set at 0.05.
MFA was performed using SPAD Software. All the other
data processing and analyses were performed with SAS
Software for Windows (Statistical Analysis System, ver-
sion 9).
Results
Population characteristics
Socio-demographic and clinical characteristics of the
"pooled" population set that was used in the analyses are
summarised in Table 1. The "pooled" population con-
sisted of 652 patients, amongst whom 234 were from the
United States, 309 from the Netherlands and 109 from
France. Of these 652 patients, 426 patients had AF, 87 had
DVT and 139 had PE. The mean age was 65 years, patients
with AF being the oldest population (mean = 68 years-
old). Overall, males were more represented than females,
with the greatest difference observed within the AF popu-
lation (70% men).Health and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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Challenging the original PACT-Q structure
The analyses were performed with the "scoring and initial
validation" population subset (n = 452), including
patients with AF (n = 226), DVT (n = 87) and PE (n = 139)
from France (n = 109), the Netherlands (n = 209) and the
United States (n = 134).
Finalisation of the PACT-Q: initial validation of the original structure 
and scoring
The PCA with Varimax Rotation and MA were conducted
on the PACT-Q1 completed at Day 1. The PCA performed
on the 7 items of PACT-Q1 resulted in the definition of 2
factors with eigenvalues greater than 1, accounting for
only 23% (Factor 1, containing items A3, A5 and A7) and
18% (Factor 2, containing items A1, A2, A4 and A6) of the
total variance. Correlations between the 7 items were very
low, with Pearson coefficients ranging from -0.068 to
0.268, indicating that the items were non-redundant.
Cronbach's alpha was low (0.43). Item-dimension corre-
lation coefficients ranged from 0.12 to 0.29, reflecting low
item convergent validity criteria. Taken together, these
data indicated that the "Treatment Expectations" dimen-
sion was not unidimensional. Each of the items of this
dimension will therefore be analysed separately.
Following PCA analysis with Varimax Rotation conducted
on the PACT-Q2 part completed at M3, four factors were
retained based on an eigenvalue greater than one, repre-
senting 53% of the total variance. Factor 1 contained all
items of the original "Convenience" dimension (i.e. B1 to
B9), except B10 and B11; factor 2 contained items D4 to
D7 of the original "Anticoagulant Treatment Satisfaction"
dimension; factor 3 the items B10, B11 of the "Conven-
ience" dimension and the items C1 and C2 of the "Burden
of Disease and Treatment" dimension; factor 4 the items
D1, D2 and D3 of the original "Anticoagulant Treatment
Satisfaction" dimension. MA results showed good item
convergent validity criteria for all the items within their
own respective dimension, except items B10 and B11
("Convenience" dimension) and items D2 and D3 ("Anti-
coagulant Treatment Satisfaction" dimension). All items
reached the discriminant validity criterion, i.e. all items
shared a higher correlation with their own dimension
than with the other dimensions of the questionnaire.
Cronbach's alpha was satisfactory for the "Burden of Dis-
ease and Treatment" dimension (0.66), and good for the
"Anticoagulant Treatment Satisfaction" and the "Conven-
ience" dimensions (0.79 and 0.82, respectively). No ceil-
ing effects were reported, whereas a floor effect was
observed for the "Burden of Disease and Treatment"
(57%) and "Convenience" (26%) dimensions.
To improve the measurement model of the PACT-Q2, sev-
eral alternative models were further tested for their struc-
ture, amongst which one model was retained as it
displayed the most satisfactory and stable properties. The
retained model included 2 dimensions ("Convenience",
containing all B and C items, and "Anticoagulant Treat-
ment Satisfaction" dimension, containing all D items). All
the items within each of the PACT-Q2 dimensions met the
convergent validity criterion (ranging from 0.42 to 0.66),
except items B10 and B11, and items D2 and D3. All items
met the item discriminant validity criterion. A floor effect
was still observed for the "Convenience" dimension; no
ceiling effect was noted for the 2 dimensions. The respec-
tive Cronbach's alpha values were 0.83 and 0.79 for the
"Convenience" and "Anticoagulant Treatment Satisfac-
tion" dimensions. The correlation coefficient between the
2 dimensions was low (-0.25), confirming that they
clearly covered two separate concepts.
Thus, the final PACT-Q2 was constituted of 2 dimensions:
the "Convenience" dimension, comprising items B1 to
B11 (from the original "Convenience" dimension) com-
bined with items C1 and C2 (from the original "Burden of
Disease and Treatment" dimension), and the "Anticoagu-
lant Treatment Satisfaction" dimension containing items
D1 to D7 (Figure 2). The structure, dimensions and
detailed contents of the items of the final version of PACT-
Q are reported in Table 3.
Table 1: Socio-demographic and clinical characteristics of the "pooled" population at day 1 (n = 652)
Medical condition Number of patients Countrya (n) Age
(years ± SD)
Gender (%) INRb, c (n) Patients with prior 
medicationd (n)
US NL FR Male Female <2 [2;3] >3
Atrial fibrillation 426 152 251 23 68 ± 9.5 70 30 152 207 64 72
Deep venous 
thrombosis
87 58 0 29 54.6 ± 16.8 48 52 77 0 0 0
Pulmonary 
embolism
139 24 58 57 59.9 ± 16.4 52 48 11 1 0 0
a US, The United States; NL, The Netherlands; FR, France
b INR, International Normalized Ratio; MD
c MD, missing data = 39
d Patients who had already received antithrombotic agents prior to participation in the studyHealth and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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The final PACT-Q1 remained similar to the original ver-
sion, i.e. containing 7 items, each individually scored
from 1 to 5; for items A1, A2, A4 and A5, the higher the
score, the higher the patients' expectations of their treat-
ment; for items A3, A5 and A7, the lower the score, the
higher the patients' expectations of their treatment (Table
2). Within the PACT-Q2, items B and C are reversed,
summed and rescaled on a 0–100 scale to obtain the
"Convenience" dimension score (Table 2). The higher the
score, the higher the convenience and the lower the bur-
den as perceived by the patient for their treatment. Items
D are summed and rescaled on a 0–100 scale to determine
the "Anticoagulant Treatment Satisfaction" dimension
score (Table 2); the higher the score, the higher the patient
satisfaction with their anticoagulant treatment.
Studies of the link between PACT-Q1 and PACT-Q2
Pearson correlation coefficients between PACT-Q1 and
PACT-Q2 (final structure) were below 0.20 for the major-
ity of the items, indicating a weak relationship between
the "Treatment Expectations" items and those assessing
the "Convenience" and "Anticoagulant Treatment Satis-
faction". RV coefficients between PACT-Q1 at Day 1 and
PACT-Q2 at M3 were also low, ranging from 0.032 to
0.040, showing weak links between the dimensions of the
two PACT-Q parts.
Validation and psychometric properties of the final PACT-
Q dimensions
MA was first conducted with the "scoring and initial vali-
dation" population subset (n = 452). In order to use a sub-
set of patients that had not been used for the scoring, the
robustness of the PACT-Q structure was then validated
with the "robustness" population subset (n = 200). A fur-
ther analysis with the "pooled" population set (n = 652)
allowed the validation to be consolidated.
Regardless of the country, the quality of completion of
PACT-Q1 at Day 1 was good in the "pooled" population,
with 1.1% missing data. For PACT-Q2, completion was
still good though slightly lower, with 2.4% missing data at
M3, and 1.5% missing data at M6.
Percentages of responses allocated to each of the response
choices at Day 1 for the "Expectations" items are repre-
sented on Figure 3. The majority of patients answered "A
lot" or "Extremely" for items A1, A2, A4 and A6. The
majority of patients answered "Not at all" or "A little" for
items A3, A5 and A7. Scores of the "Convenience" and
"Anticoagulant Treatment Satisfaction" at M3 and M6 are
summarised in Table 4. "Convenience" scores decreased
from 91.3 at M3 to 90.6 at M6; "Anticoagulant Treatment
Satisfaction" scores slightly increased from 68.9 to 70.6,
respectively.
Item convergent validity, floor and ceiling effects and
internal consistency reliability of the PACT-Q2 dimen-
sions obtained for these two subsets of population and
the "pooled" population are summarised in Table 4.
Conceptual framework of the final PACT-Q Figure 2
Conceptual framework of the final PACT-Q.
 

 
 
  
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Item convergent and discriminant validity criteria
Overall (i.e. in the "pooled" population), all the items
within the "Convenience" dimension, except items B10
and B11, met the item convergent criteria and ranged
from 0.33 to 0.64. All the items within the "Anticoagulant
Treatment Satisfaction" dimension met the convergent
criterion, except items D2 and D3, and ranged from 0.33
to 0.63. All the items of the 2 dimensions reached the item
discriminant validity criterion.
Scale-scale correlation
The correlation coefficient between the "Convenience"
and "Anticoagulant Treatment Satisfaction" dimensions
of the PACT-Q2 was moderate (0.29), reflecting a fair rela-
tionship and no redundancy between the 2 dimensions.
Floor and ceiling effects
No floor effect was observed for either dimension of the
PACT-Q2. No ceiling effect was noted for the "Anticoagu-
lant Treatment Satisfaction" dimension, contrary to the
"Convenience" dimension (percentage of patients at the
highest possible score = 22%).
Internal consistency reliability
Good internal consistency reliability was displayed within
each of the PACT-Q2 dimensions, with Cronbach's alpha
Table 2: Dimensions, detailed concepts and scoring method of the final PACT-Q
PACT-Q Dimensions Item number – Detailed concept Scoring Score range
PACT-Q1 Treatment Expectations A1 – Confidence in prevention of blood clots One score 1 to 5
A2 – Expectations of symptom relief One score 1 to 5
A3 – Expectations of side effects One score 1 to 5
A4 – Importance of ease of use One score 1 to 5
A5 – Worries about making mistakes One score 1 to 5
A6 – Importance of independency One score 1 to 5
A7 – Worries about cost One score 1 to 5
PACT-Q2 Convenience* B1 – Difficulties in taking the treatment One score 0 to 100
B2 – Bother in taking the treatment
B3 – Difficulties regarding dose adjustments required
B4 – Treatment and other medications
B5 – Treatment and regimen implications
B6 – Treatment and being away from home
B7 – Difficulties regarding daily life
B8 – Bother in follow-up required
B9 – Difficulties regarding regular intake
B10 – Feeling regarding loss of independency
B11 – Worries about having to stop the treatment
C1 – Impact of side effects on usual activities
C2 – Discomfort due to symptoms
Anticoagulant Treatment Satisfaction* D1 – Feeling of reassurance One score 0 to 100
D2 – Symptom decrease
D3 – Experience with side effects
D4 – Satisfaction regarding independency
D5 – Satisfaction with patient management
D6 – Satisfaction with treatment form
D7 – Overall satisfaction
* For convenience score, all items are reversed (reversed item score = 6 – initial item score), then summed and rescaled on a 0 – 100 scale; for 
satisfaction score, all items are summed and rescaled on a 0 – 100 scale; for both scores, the higher the score, the higher the convenience/
satisfaction
Table 3: Description of PACT-Q2 dimension scores at M3 and M6
PACT-Q2 dimensions N Mean (STD) Median (Q1 – Q3) Min – Max
M3 Convenience 651 91.3 (10.4) 94.2 (88.5 – 98.1) 32.7 – 100.0
Anticoagulant Treatment Satisfaction 641 68.9 (17.0) 67.9 (57.1 – 79.2) 0.0 – 100.0
M6 Convenience 404 90.6 (10.4) 94.0 (86.5 – 98.1) 23.1 – 100.0
Anticoagulant Treatment Satisfaction 403 70.6 (17.4) 71.4 (60.7 – 82.1) 0.0 – 100.0Health and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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values of 0.84 for "Convenience", and 0.76 for "Anticoag-
ulant Treatment Satisfaction".
Known-group validity
Scores of items A2, A4, A5 and A7 within the "Treatment
Expectations" dimension at Day 1 (PACT-Q1), and the
"Convenience" and "Anticoagulant Treatment Satisfac-
tion" dimensions at M3 showed significant differences
when compared according to the age of the patients: the
highest scores of "Treatment Expectations" items were
observed for patients under 60 years of age (data not
shown). Patients aged between 60 and 65 displayed
higher "Anticoagulant Treatment Satisfaction" scores than
younger and older patients, this difference being signifi-
cant (p = 0.028). For the "Convenience" dimension, the
highest score was observed for patients aged between 65
and 75 years (p < 0.0001). Only the A2, A3 and A7 item
scores of "Treatment Expectations" were significantly dif-
ferent between females and males, while other scores were
similar over the 2 groups. When compared according to
experience of prior medication, scores of the "Conven-
ience" dimension were significantly higher for patients
who did not have prior medication than patients who did
(score of 92 versus 89, respectively; p = 0.01). A higher
score was reported at item A2 ("Treatment Expectations"
– symptom relief) for patients with no prior medication
experience than for patients with experience (3.3 versus
2.8, p = 0.0044). In contrast, a significantly higher score
for item A3 ("Treatment Expectations" – side effects) was
observed for patients with prior experience of medication
than patients with no prior medication (2.9 versus 2.4, p
= 0.0003). Scores in the "Anticoagulant Treatment Satis-
faction" dimension were higher for patients who reported
no events within 3 months of randomisation than for
those who reported having had an event (69 versus 41,
respectively; p = 0.005).
When compared between groups of patients defined
according to their baseline INR level at Day 1 (i.e. < 2,
[2;3], > 3), scores of most items of PACT-Q1 (item A2,
"symptom relief"; item A3, "side effects"; A4, "ease of
use"; A5, "making mistakes"; and A7, "cost of the treat-
ment") were significantly higher for patients with INR < 2
than for patients with INR = 2. Regarding PACT-Q2 at M3,
the "Anticoagulant Treatment Satisfaction" score was the
lowest for patients with an INR > 3, and significantly
increased as INR decreased (scores ranging from 61 to 69).
These results at M3 concerned only patients treated with
VKA as the INR was not available after Day 1 for patients
treated with the new anticoagulant treatment. None of the
other differences observed between scores of the PACT-
Q2 dimensions or PACT-Q1 items were significant.
Similarly, score differences reported between groups of
patients defined according to the time they spent in the 2–
3 INR range (4 groups defined: < 50%, between 50% and
60%, between 60% and 70%, and  70%) were not signif-
icant. In other terms, the time spent in the 2–3 INR range
between randomisation and M3 does not have a statisti-
cally significant impact on scores. Again, these results con-
cerned only patients treated with VKA, as those treated
Table 4: Psychometric validation of the PACT-Q2 dimensions for the 3 population subsets
Population subsets Cronbach's alpha Floor effectc (%) Ceiling effectd (%) Convergent and discriminant 
validity criterion
(range of item-scale correlations)
"scoring and initial validation" (n = 452)
Convenience 0.83 0 21.2 0.31–0.63
Anticoagulant Treatment 
Satisfaction
0.79 0.6 4.0 0.36–0.66
"robustness" (n = 200)
Convenience 0.87 0 24.1 0.40–0.67
Anticoagulant Treatment 
Satisfaction
0.70 0 1.9 0.26–0.59
"pooled" (n = 652)
Convenience 0.84 0 22.1 0.33–0.64a
Anticoagulant Treatment 
Satisfaction
0.76 0.4 3.3 0.33–0.63b
a except items B10 and B11, all items meet the convergent validity criterion
b except items D2 and D3, all items meet the convergent validity criterion
c percentage of patients with the lowest possible score (i.e. 0), that is patients who answered the least favourable response choice to all items of the 
dimension.
d percentage of patients with the highest possible score (i.e. 100), that is patients who answered the most favourable response choice to all items of 
the dimension.Health and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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with idraparinux did not have INR monitoring during the
study.
Change of PACT-Q2 scores over 3 months
Overall, no significantly different changes in the "Conven-
ience" and "Anticoagulant Treatment Satisfaction" scores
were observed from M3 to M6, whether compared
between groups of patients defined according to their
report of a thromboembolic event (or not) within 3
months of randomisation, the time they spent within the
2–3 INR range between randomisation and M3, and M3
and M6, or the impact of the INR control status deteriora-
tion or improvement. Most of the changes in scores
observed within each group were not significantly differ-
ent to 0 (p-signed rank test > 0.05).
Discussion
The PACT-Q was included as a secondary endpoint in
phase III clinical trials in order to assess the expectations
and satisfaction of patients suffering from DVT, PE or AF
and treated with a new long-acting anti-thrombotic drug
injected once a week subcutaneously, in comparison with
an oral VKA treatment. The finalisation and psychometric
validation steps of the questionnaire were performed
using the patients of the clinical trials.
Validity of the original PACT-Q structure
Regarding the PACT-Q2 part, the exploratory PCA per-
formed on the original PACT-Q revealed a structure very
close to the proposed original structure [11], with 4 fac-
tors covering treatment convenience (items B1 to B9),
treatment satisfaction (items D4 to D7), burden of disease
and treatment and convenience of use (items C1 and C2
and items B10 and B11, respectively), and patients' anti-
coagulant treatment satisfaction (items D1 to D3). The
overall good homogeneity of the PACT-Q2 dimensions,
as reflected by the Cronbach's alpha values of 0.79 ("Anti-
coagulant Treatment Satisfaction" dimension) and 0.82
("Convenience" dimension), confirmed the well-founded
hypothesis of the original structure of the questionnaire.
The lower value (0.66) reported for the "Burden of Dis-
ease and Treatment" dimension is perfectly acceptable as
it contains only 2 items. As for the PACT-Q1 part, the
weak correlations between each of the items and their low
item convergent validity criterion, together with the low
internal consistency reliability of the "Treatment Expecta-
Description of the percentage of patients per response choice to the "Expectations" items at Day 1 (N = 652) Figure 3
Description of the percentage of patients per response choice to the "Expectations" items at Day 1 (N = 652).
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tions" dimension, strongly suggests that the items of
PACT-Q1 cannot be thought of as one single concept.
Scoring and psychometric validation of the PACT-Q
The last series of PCA and MA led to the conclusion that
the 7 items of the "Treatment Expectations" of PACT-Q1
were to be scored individually. This is not surprising as
expectations cover heterogeneous concepts, each of them
being measured by a single item. After the last finalisation
step, the PACT-Q2 was reduced from 3 to 2 dimensions
covering treatment "Convenience" (13 items) and "Anti-
coagulant Treatment Satisfaction" (7 items). The number
of items in the 2 dimensions is quite high, and one could
wish to reduce the PACT-Q to a short form. However, no
items were removed as they were all relevant for the pur-
pose of the questionnaire and the concepts were shown to
be pertinent and well-accepted by patients. The use of
PACT-Q in further clinical studies would be needed to
definitively confirm their relevance. The reliability of
these findings is increased by the use of separate subsets of
population for the scoring and initial validation and for
the psychometric validation.
The good quality of completion and returns of both
PACT-Q1 and PACT-Q2 in all of the countries reflected
the good acceptability of the questionnaire. The PACT-Q2
structure was further confirmed by a good item conver-
gent and discriminant validity criterion and excellent
internal consistency reliability of both dimensions. No
floor or ceiling effects were observed for the "Anticoagu-
lant Treatment Satisfaction" dimension; in contrast, a ceil-
ing effect (22%) was reported for the "Convenience"
dimension. While a ceiling effect is not recommended
when measuring quality of life aspects [21], it is easily
conceivable and acceptable that a majority of patients
report no inconvenience of use in their treatment, partic-
ularly in clinical trials.
Known-group validity showed that PACT-Q dimensions
were able to discriminate between groups of patients pre-
senting different disease experiences and characteristics.
In particular, patients who had had no previous experi-
ence of anticoagulant treatment were significantly more
demanding in terms of symptom relief, while patients
who had already been treated with anticoagulants
expected more side effects than those who had not, and
could therefore possibly be more realistic. These findings
agree with Oliver's work, who proposed that patients'
expectations are considerably influenced by previous
experiences and knowledge that they have acquired of
their disease and treatment [10]. As expected, patients' sat-
isfaction was greater if they did not have a thrombolic
event within the period of time that they were under treat-
ment. In addition, one should point out that although a
few patients only (n = 4) experienced an event within
these 3 months, this had a noticeable impact on their sat-
isfaction, thus indicating that PACT-Q is sensitive to
events that are meaningful to patients. Lastly, patients at
risk of embolism (INR < 2) at Day 1 of the study expected
much more from their anticoagulant treatment in terms of
cost, ease of use, side effects, worries about making mis-
takes and symptom relief, when compared to patients
with lower risk of embolism (INR > 3). After 3 months of
anticoagulant treatment, patients with an INR > 3 (i.e.
with less risk of embolism) were the most satisfied with
their treatment compared to patients with a higher INR.
Interestingly, no correlation could be drawn between
patients' expectations from the anticoagulant treatment at
baseline and their satisfaction after 3 months of treat-
ment. This can be explained by the theoretical model of
Oliver et al., in which the authors propose that patients
derive their satisfaction from the comparison between
their expectations before starting the treatment and the
performance they eventually perceive from it after being
treated [10]. Therefore, in order to study the link between
expectations and satisfaction, it would be necessary to
assess it according to the treatment patients are receiving,
which could not be performed as the statistical analyses
were blind to the treatment attribution.
The good psychometric properties demonstrated by the
PACT-Q in this paper support its use as secondary end-
point in trials. However, one should note that key valida-
tion criteria still need to be assessed before considering its
use as a primary endpoint; in particular, the assessment of
the responsiveness and test-retest reliability properties of
the questionnaire and the estimation of the value for the
minimal important difference.
Given the design of the phase III clinical trial, test-retest
reliability of the PACT-Q was not assessed. For similar rea-
sons, it was difficult to assess the responsiveness of the
questionnaire. Indeed, as the PACT-Q2 aims to assess
patients' satisfaction with their treatment and treatment
convenience, the largest difference that one could expect
should be between patients treated with VKA and patients
treated with the new anticoagulant drug. However, the
scoring procedure had to be established blinded to treat-
ment groups; comparison of patients' satisfaction
between these groups could therefore not be made in this
present study. Changes in satisfaction and treatment con-
venience, are more likely to be assessable from the treat-
ment effect longitudinal study; these data of which will be
further presented in another publication.
Conclusion
The PACT-Q is a valid and robust instrument that allows
patients' expectations and satisfaction with anticoagulant
treatment to be assessed. The good acceptability and psy-
chometric properties of the questionnaire have been dem-Health and Quality of Life Outcomes 2009, 7:30 http://www.hqlo.com/content/7/1/30
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onstrated with patients with various conditions including
DVT, PE and AF, suggesting the PACT-Q's suitability for
thromboembolic pathologies in general. Its multi-lan-
guage validated versions will facilitate and widen its use in
international studies.
This instrument could be helpful for clinicians to identify
patients' expectations, either positive or negative, of their
anticoagulant treatment. Together with a better knowl-
edge of how patients perceive their treatment, the ques-
tionnaire could therefore contribute to facilitate
physicians' decision about the most appropriate medical
care for their patients; this would probably result in a bet-
ter compliance from patients, and ultimately in a better
control of the disease.
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